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ABSTRACT 
Brilliant, valid and simple five UV spectrophotometricstability indicating techniques are adopted for the determination of 
Gemifloxacin (GEM) in presence of its acid degradation products over a concentration range of 2-12 μg mL
-1
. The first 
method is an application of the first derivative (
1
D) spectrophotometry, that allows the determination of GEM without 
interference of its acid degradation products at zero crossing wavelength (254.6 nm). The second method depends on the 
first-derivative of the ratio spectra spectrophotometry (
1
DD) for determination of GEM in presence of its acid degradation 
products at a maximum of 273.0 nm and a minimum of 284.0 nm, While the third dual wavelength method offers a 
superior stability indicating procedures for the determination of GEM in the zero order spectra at the wavelength pair of 
271.8 nm and 325.0 nm. The fourth method is the ratio difference one, with the advantages of minimal data processing 
and wide range of application. It is applied for the analysis of intact drug in presence of its acid degradation products by 
measuring the difference in the peak amplitude at the ratio spectra at 355.0 nm and 270.0 nm. The last method is based 
on the quantification of GEM through the bivariate calibration at 255.0 nm and 277.0 nm by adopting simple mathematic 
algorithm that provides simplicity and rapidity.  
Keywords: Gemifloxacin; first derivative; derivative ratio;dual wave length; bivariate calibration; ratio difference. 
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1. INTRODUCTION 
Gemifloxacin; chemically is 7-[(3-(Aminomethyl)-4-(methoxyimino)-1-pyrrolidinyl]-1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-
1,8-naphthyridine-3-carboxylic acid 
[1]
, Figure (1). It is an oral broad-spectrum third generation fluoroquinolones 
antibacterial agent used in the treatment of acute bacterial exacerbation of chronic bronchitis and mild-to-moderate 
pneumonia. It is indicated for the treatment of respiratory and urinary tract infection
[2]
. Gemifloxacin (GEM) is rapidly 
absorbed from the gastrointestinal tract with an absolute bioavailability of about 71%. A peak plasma concentration is 
occurring 0.5 to 2 hours after an oral dose. It undergoes limited hepatic metabolism and has an elimination half –life of 
about 7 hours. It is excreted as unchanged drug and metabolites in the faeces and urine
 [3]
. 
Several analytical techniques were widely described for the analysis of GEM. Some spectroscopic methods with different 
approaches including colorimetric 
[4-7]
, and fluorimetric
[8]
 procedures were developed. GEMcan also be determined byLC-
tandem MS
 [8-12]
 and thin layer chromatography 
[13]
. Different high performance liquid chromatographic [HPLC] methods 
were used for analysis of GEM in variable sample matrices
[14-25].
But according to the literatures in hands, there is no direct 
stability indicating spectrophotometric method was developed for GEM quantification. 
2. EXPERIMENTAL 
2.1. Instrumentation 
Dual-beam UV-visible spectrophotometer, UV-1650 PC (Shimadzu) with matched 1 cm quartz cells, connected to an IBM 
compatible personal computer (PC), software is UV Probe version 2.21 
2.2. Materials and reagents 
• Gemifloxacin (GEM) pure sample,HIKMA Pharma, Giza-Egypt. Its purity was assessed to be 99.61± 0.579 % (n= 6) 
according to a reported spectrophotometric method
 [4].
 
• Factive® tablets,each tablet claimed to contain426.39 mg gemifloxacin mesylate equivalent to 320 mg gemifloxacin, 
batch No.(BN) 005 ,  manufactured by HIKMA Pharma S.A.E-Egypt, under license of LG life science ,Ltd , Seoul-Korea. 
• Methanol: Spectroscopic grade (E. Merck, Darmstadt- FRG).  
• Sodium hydroxide, 4M aqueous solution and hydrochloric acid, 3M aqueous solution (Adwic, Cairo-Egypt).   
2.3. Standard solutions 
2.3.1Standard solution of Gemifloxacin 
A standard stock solution of GEM was prepared by transferring accurately 100 mg of pure drug into 100-mL volumetric 
flask, dissolving in 20 mL methanol and then the volume was completed to the mark with the same solvent to provide 
standard stock solution containing 1mg mL
-1
. 
2.3.2. Working solution of Gemifloxacin 
GEM working solution was prepared by transferring 10 mL of the standard stock solution into100-mL volumetric flask and 
then the volume was completed to the mark with methanol to obtain standard working solution containing 0.1mg mL
-1 
of 
GEM, and then further dilution was applied to reach final concentration of 10μg mL
-1
. 
2.3.3. Stock solution of acid degraded GEM 
     Accurately weighed 100 mg of pure GEM was transferred to a 250-mL round bottomed flask and 25 ml of 3N HCL was 
added, and then refluxed with continuous magnetic stirring for 10 hrs. The solution was neutralized to pH 7 with 4N NaOH, 
concentrated nearly to dryness and cooled to room temperature.  The residue was dissolved with least amount of 
methanol, and then filtered, the filtrate was collected into 100 ml measuring flask and the volume was made up with 
methanol. Complete acid degradation of GEM was confirmed by TLC –fractionation on silica gel F 254 plates using  ethyl 
acetate : methanol : ammonia ( 8:4:3 by volumes as a developing solvent , visualization was carried under UV –lamp 
254.0 nm 
[14]
 . Then the degradation products were elucidated by mass spectrometry.  
Aliquot portion of this solution was diluted with distilled water to prepare working stock solution of 10μg mL
-1
.  
2.5. Procedures 
2.5.1. Construction of calibration curves 
 Accurately measured volumes of intact GEM working solution (0.1mg mL
-1
) were transferred into a series of 10-mL 
volumetric flasks and diluted to the mark with methanol to obtain concentrations from 2 to 12 μg mL
-1
. These prepared 
concentrations were used to construct the calibration curve for each theory as follows: 
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2.5.1.1. For D1 spectrophotometric method. 
The D
1 
spectra of each solution was recorded using Δλ = 4 and scaling factor = 20. For determination of GEM in presence 
of its acid degradation products, calibration curve was obtained by plotting the peak amplitudes of D
1
 at 254.6 nm 
(corresponding to zero-crossing of the degradation products) versus the corresponding drug concentrations, and 
regression equation was computed. 
2.5.1.2. For (DD1) spectrophotometric method.  
The absorption spectra of these solutions were divided by the absorption spectrum of 8 μg mL
-1
 of the acid degradation 
products (as divisors). The obtained ratio spectra were then differentiated with respect to wavelength usingΔλ= 4 and 
scaling factor = 1. The peak amplitudes at peak 273.0 nm and trough 284.0 nm were recorded for the determination of 
GEM in presence of its acid degradation products. The calibration curves representing the relationship between the 
measured amplitudes and the corresponding concentrations of the drug were constructed and the regression equations 
were computed.  
2.5.1.3 For dual wave length method. 
The Zero-order spectrum of each dilution was recorded against methanol as blank. The absorbance difference of GEM 
was measured between the selected wavelength pair (271.8 nm & 325.0 nm) for each dilution separately,and then the 
obtained differences were plotted against the corresponding concentrations of the drug and the regression equation was 
then computed. 
2.5.1.4. For ratio difference spectrophotometric method: 
The zero order spectra of the prepared concentrations of GEM were divided by the spectra of 8 μg mL
-1 
GEM acid 
degradation product, the difference in the peak amplitudes at the ratio spectra was measured at 355.0 and 270.0 nm (ΔP)  
. Calibration graph relating ΔP at the chosen wavelength couples to the corresponding concentrations of GEM was 
constructed, and the corresponding regression equation was computed. 
2.5.1.5. For bivariate spectrophotometric method. 
A concentration series of the acid degradation products was prepared as well. Accurately measured volumes from its 
working solution were transferred separately into a series of 10-mL volumetric flasks and diluted to the mark with methanol 
to obtain concentrations from 2 to12 μg mL
-1
. The Zero-order spectrum of each dilution was recorded against methanol as 
blank. The absorbance of GEM and its acid degradation products were measured at 255.0 nm and 277.0 nm for each 
dilution separately, and then the absorbance at the selected wavelengths were plotted against the corresponding 
concentrations and the regression equations were then computed. 
2.5.2. Laboratory prepared mixtures 
Laboratory synthetic mixtures containing GEM and different percentages of its degradation product were prepared by 
transferring aliquot portions (1 – 9 mL) of the GEM working solution in a concentration of (10 μg mL‎
-1
) into a series of 10-
mL measuring flasks. Different portions of the acid degraded solution its concentration is 10 μg mL
-1
were also added to 
prepare different mixtures containing 10 - 90% of the degradation products then the volumes were made up with 
methanol. 
2.5.3. Application to pharmaceutical preparation 
Ten Factive
®
 tablets were powdered finely, a weight equivalent to ~ 100 mg GEM was transferred accurately into a 100-
mL volumetric flask and sonicated for~20 min with about 50 mL methanol, followed by filtration through filter paper then 
the volume was completed with methanol to 100 mL. Further dilutions were applied with methanol in order to reach the 
linearity rang. The general procedures were followed and the concentration of GEM was calculated from its corresponding 
regression equations. 
3. RESULTS AND DISCUSSION 
The focus of the present work was to develop accurate, specific, and sensitive stability indicating methods for the 
determination of GEM in pure form and in pharmaceutical formulation in presence of its potential acid degradation 
products. 
3.1. Separation and identification of degradation products 
Accelerated stability studies were applied to GEM to explore its inherent stability characteristics and it was found that GEM 
is susceptible to hydrolysis under acidic conditions. The expected scheme of acid degradation of gemifloxacin may be 
illustrated as shown in Scheme (1).The structure of the acid-induced degradation products was confirmed using mass 
spectral analysis as shown in Figure (2).The zero-order absorption spectra of GEM and its acid degradation products 
show sever overlapping, Figure (3), which interferes with the direct determination of GEM. This problem suggested that 
these proposed methods are suitable method for the simultaneous determination of GEM in presence of its acid 
degradation products. 
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3.2. D1  method: 
The obtained spectra showed good resolutions allowing clear determination of GEM at 254.6 nm without any contribution 
of its degradation products that show zero crossing at the selected wavelength, Figure (4). Linear calibration curves were 
obtained for the suggested method in concentration range of (2-12 μg mL
-1
). The regression equation was calculated and 
found to be: 
1
DGEM ═ 0.0585 C + 0.0142      (r = 0.9997).  
1
D: Peak amplitude of first derivative. C: Concentration (μg mL
-1
), r: Correlation Coefficient. 
3.3. 1 DD method: 
1
DDvalues showed good linearity and reproducibility at a peak 273.0 nm and a trough 284.0 nm without interference from 
its acid degradation products Figure (5). Linearity of the peak amplitudes of the 
1
DD curves at both wavelengths was 
obtained in the range of 2-12 μg mL
-1
 and the regression equations were computed as shown below: 
1
DD = 0.0767 C - 0.0629                (r = 0.9994)          (273.0 nm) 
1
DD = 0.1014 C - 0.0656                (r = 0.9996)          (284.0 nm)       
Where, 
1
DD:  peak amplitude of first derivative of the ratio spectra.  
C    :  Concentration (µg mL
-1
),           r    :  Correlation coefficient. 
3.4.Dual wavelength method: 
Dual wavelength method copes with the level of interference when the spectra as strongly overlapped as shown in Figure 
(3), It uses the analytical signal data at two accurately selected wavelengths, thus appropriate selection, thus appropriate 
selection of wavelength pair is very important. To select the appropriate wavelength pair, the following principles were 
applied: at the selected wavelengths, the difference in analyte signals had to be linear while the difference in interferent 
signal is remaining zero with changing the concentration. In addition, the analytical signal obtained from a mixture of the 
analyte and the interferent should be equal to the sum of the individual signals of the two species. Also, the difference in 
absorbance due to the analyte signal at the two selected wavelengths should be as large as possible in order to reach 
good accuracy and sensitivity 
[26]
. 
To optimize the method, different pairs of wavelengths were selected and tried to show zero absorbance difference for the 
GEM acid degradation products with maximum difference in absorbance due to GEM, 271.8 nm and 325.0 nm were 
selected for the determination of GEM, where the acid degradation product shows the same absorbance. A linear 
Calibration curve was obtained in the range (2-12 μg mL
-1
) relating the difference between the absorbance at the two 
selected wavelengths 271.8 nm and 325.0 nm to the corresponding drug concentrations in presence of acid degradation 
product and the regression equation was calculated and found to be:  
Δ PGEM        = 0.0581 C – 0.0253        (r = 0.9998). 
Where, Δ P: Absorbance difference at the two selected wavelengths (271.8 and 325.0 nm).          
C    :  Concentration (µg mL
-1
)   , r    :  Correlation coefficient. 
3.5. Ratio difference spectrophotometric method: 
A smart ratio-difference method has been developed recently with the advantages of minimal data processing and wide 
range of application, in addition to the advantages of ratio spectra manipulation 
[27]
, Figure (6).   The linear regression data 
for the calibration curve showed a good linear relationship over a concentration range of 2 - 12 μg mL
-1
 and the regression 
equation was computed and found to 
ΔP = 0.7113 C + 0.0927   (r = 0.9996).   Where,  
ΔP:  Absorbance difference at the two selected wavelengths.  
C: Concentration (µg mL
-1
), r :  Correlation coefficient. 
3.6. Bivariate Calibration Method 
GEM was also determined and resolved from its acid degradation products by using bivariate calibration 
spectrophotometric method, which is based on a simple mathematical algorithm. The method has been successfully 
applied to resolve different binary mixtures 
[28, 29]
,   in which the data is used derives from four linear regression calibration 
equations, two calibrations for each component at two wavelengths selected using the method of Kaiser
 [30]
, whichwas 
used for the selection of optimum wavelength set which assured the best sensitivity for the quantitative determination of 
the studied drug
. 
In order to apply this method, the signals GEM and its acid degradation products located at six 
wavelengths: 255.0, 270.0, 277.0, 310.0, 320.0, and 340.0 nm were selected. 
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The determinants of these matrices were calculated as shown in Table (1). The wavelength set (255.0 and 277.0) nm was 
selected for which the highest matrix determinant value was obtained. 
Table (2) showed the linear regression calibration formula used for bivariate algorithm. 
3.7. Method validation 
Method validation is an integral part of the analytical procedure; therefore full validation study was done for each proposed 
method. Analytical figures of merits were applied in agreement with ICH guidelines
 [31] 
by measuring range, accuracy, 
precision, repeatability, interday precision, linearity, application of dosage form, application of standard addition technique 
and specificity. Results obtained are depicted in Tables (3-5). 
4.CONCLUSION: 
The proposed methods are accurate, precise and reproducible. They are stability-indicating methods. These methods 
complied with the validation guidelines of the International Conference on Harmonization and could be used for purity 
testing, stability studies, quality control, and routine analysis of GEM either in its bulk powder or in dosage form without 
noticeable interference from other common dosage form additives. The obtained results were statistically non-significant 
when they have been compared with those of the reference method. 
Table 1: Application of the method of Kaiser for the selection of the wavelength set for the determination of GEM. 
λ1/λ2 255.0 270.0 277.0 310.0 320.0 340.0 
255.0 0 1353.56 1563.48 -27.84 87.02 524.82 
270.0  0 538.98 -520.26 -531.05 -217.23 
277.0   0 -589.86 -648.06 -459.9 
310.0    0 44.37 206.19 
320.0     0 191.94 
340.0      0 
 
Table 2 : Linear regression calibration formulae used for the bivariate algorithm. 
Component Calibration equations 
 λ 1=255.0nm λ 2=277.0nm 
Gemifloxacin 
A= 0.0500C + 0.0163 
r= 0.9992. 
A= 0.0822C -0.0378 
r=0.9992 
Acid degradation products 
A= 0.0234 C + 0.0151 
r = 0.9992 
A= 0.0072 C + 0.0041 
r = 0.9997 
 
A =Absorbance at the selected wavelength. 
C = Concentration in μg mL
-1
.    r = Correlation coefficient.
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Table  3: Results of validation parameters of the responses and the regression equations obtained by the 
proposed methods 
Validation parameters 
D
1
-method 
254.6 nm 
1
DD-method Dual-
wavelength 
method 
Ratio-difference 
method 
Bivariate method 
273.0 nm 284.0 nm 255.0nm  277.0nm 
Accuracy ( mean ± % RSD) 
99.67 ± 
0.799 
99.91 ± 
0.829 
100.01±0.304 
100.29  ±  
1.107 
99.97 ± 0.637 99.87 ±  1.254 
Specificity ± % RSD 
99.67 ± 
0.689 
100.32 
±0.796 
99.75 ± 0.730 99.53 ± 0.399 101.23 ±1.360 100.14 ± 1.533 
Range (μg mL
-1
) 2.0 -12.0 
Slope 0.0585 0.0767 0.1014 0.0581 0.7113 0.0500 0.0822 
Intercept 0.0142 -0.0629 -0.0656 -0.0253 0.0927 0.0163 - 0.0378 
Correlation coefficient (r) 0.9997 0.9994 0.9996 0.9998 0.9996 0.9996 0.9996 
P
re
c
is
io
n
 Repeatability* 0.381 0.276 0.720 0.215 0.562 1.102 
Intermediate 
Precision** 
0.714 1.072 0.924 0.326 1.247 1.241 
LOD (μg.mL
-1
)*** 0.282 0.425 0.348 0.253 0.325 
λ 1 = 0.356 , λ 2 
=0.355 
LOQ (μg.mL
-1
)*** 0.853 1.288 1.053 0.765 0.984 λ 1 = 1.078 , λ 2 =1.076 
 
*The intraday (n = 9), average of three different concentrations repeated three times within the day.  
**The interday (n = 9), average of three different concentrations repeated three times in three successive days. 
***Limit of detection and quantitation are determined via calculations, LOD = (SD of the response/slope) X 3.3; LOQ = (SD 
of the response/slope) X 10 
Table 4 : Determination of the studied drug in the laboratory prepared (L.P.) mixtures with its degradation 
products and in tablets by the proposed methods. 
Sample 
D
1
-method 
(n=6)
b
 
1
DD-method Dual 
wavelength 
Method(n= 6)
 b
 
Ratiodifferencemet
hod(n=6)
 b
 
Bivariate calibration 
method 
(n=8)
 b
 273nm(n=8)
 b
 284nm(n=7)
 b
 
L.P. mixtures 
(Mean ± SD) 
99.67 ± 0.687 100.32  ± 0.799 99.75  ± 0.728 99.53 ± 0.397 101.23 ± 1.363 100.14  ± 1.535 
Factive®  tablet 
BN:005 
( Mean ± %RSD) 
100.21 ± 
1.178 
100.10 ± 
1.941 
100.29 ±1.917 99.03 ± 0.893 99.73± 1.895 99.15 ±1.349 
Standard addition 
(Mean ± %RSD) 
100. 66 ±  1.010 99.51 ± 1.221 100.04 ± 1.131 99.96 ± 1.116 99.40 ± 0.817 100.21± 1.593 
 
b
 Sets each of 3 replicates 
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Table 5 : Statistical comparison of the results obtained by the proposed methods and the reported method for the  
determination of Gemifloxacin in pharmaceutical preparation. 
Item 
D
1
-
method 
1
DD-method Dual 
wavelength 
method 
Ratio difference 
method 
Bivariate 
calibration 
method 
Reported 
method 
** 273.0 nm 284.0 nm 
Mean 99.67 99.91 100.01 100.29 99.97 99.87 99.61 
SD 0.796 0.828 0.304 1.110 0.637 1.252 0.579 
%RSD 0.799 0.829 0.304 1.107 0.637 1.254 0.581 
n 6 6 6 6 6 6 6 
Variance 0.634 0.686 0.092 1.232 0.406 1.568 0.335 
Student ҆s t-test 
(2.228) 
0.149 0.728 1.498 1.331 1.026 0.462  
F-test (5.050) 1.89 2.05 3.64 3.68 1.21 4.73  
 
*Figures in parenthesis are corresponding theoretical   t- and F- values at p= 0.05 
(4)
 
** UV-Spectrophotometric method; a methanolic solution of Gemifloxacin was scanned between (200-400 nm), 
measured at 263.8 nm 
[4]
. 
 
 
Figure 1: Chemical structure of intact Gemifloxacin. 
 
Scheme 1 : The expected scheme of acid degradation of Gemifloxacin. 
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Figure 2 : Chromatogram of LC/MS determination of GEM    in presence of its acid degradation products, [a] for 
pure GEM, [b] for degradation product (I) and [c] for degradation (II). 
Figure 3 : Zero-order spectra of 5 µg.mL
-1
  pure GEM (___) and 5 µg.mL
-1
   acid degradation products (- - - -), using 
methanol as a solvent. 
 
Figure 4 : First derivative absorption spectra of GEM ( ____ ) and acid degradation products (- - - -), concentration 
of each is 6 μg mL
-1
 using methanol as a solvent. 
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Figure 5 : 
1
DD-Ratio spectra of  intact GEM (A) and GEM acid degradation   products (B) using a spectrum of 8 µg 
mL
-1
 of its degradation product as a divisor ,concentration of each is 6 µg mL
-1 
. 
 
 
 
Figure 6 : The ratio spectrum of 5 μg mL
-1
 intact GEM ( __ ), 8 μg mL
-1
 GEM acid degradation products( ) 
and a mixture containing 5 μg mL
-1
 intact GEM and 5μg mL
- 1
acid degradates (- - - -) using a divisor of 8 μg.mL
-1
 
degradates  in methanol.
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